Short-term ethinylestradiol treatment suppresses inferior caval vein thrombosis in obese mice

Thrombosis and Haemostasis

Volumn 102, Issue 5, 2009, Pages 993-1000

  Cleuren, Audrey C A ^a   Van Hoef, Berthe ^b   Hoylaerts, Marc F ^b   Van Vlijmen, Bart J M ^a   Lijnen, H Roger ^b  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b UNIVERSITY OF LEUVEN   (Belgium)

Author keywords

Estrogens; Mouse models; Obesity; Venous thrombosis

Indexed keywords

BLOOD CLOTTING FACTOR 10; BLOOD CLOTTING FACTOR 7; BLOOD CLOTTING FACTOR 8; CYTOKINE; ETHINYLESTRADIOL; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROTHROMBIN; SERUM AMYLOID A; BLOOD CLOTTING FACTOR; INTERLEUKIN 6; LIPID;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; FEMALE; INFERIOR CAVA VEIN; INFLAMMATION; MOUSE; NONHUMAN; OBESITY; PHENOTYPE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; TREATMENT OUTCOME; VEIN THROMBOSIS; ADIPOSE TISSUE; ANIMAL; BIOLOGICAL MODEL; BLOOD; C57BL MOUSE; DOSE RESPONSE; FAT INTAKE; LIVER; METABOLISM; ORGAN SIZE; OVARIECTOMY; PATHOLOGY; SPECIES DIFFERENCE; THROMBOPHILIA; UTERUS;

ADIPOSE TISSUE; ANIMALS; BLOOD COAGULATION FACTORS; DIETARY FATS; DOSE-RESPONSE RELATIONSHIP, DRUG; ETHINYL ESTRADIOL; FEMALE; INFLAMMATION; INTERLEUKIN-6; LIPIDS; LIVER; MICE; MICE, INBRED C57BL; MODELS, BIOLOGICAL; OBESITY; ORGAN SIZE; OVARIECTOMY; SERUM AMYLOID A PROTEIN; SPECIES SPECIFICITY; THROMBOPHILIA; UTERUS; VENA CAVA, INFERIOR; VENOUS THROMBOSIS;

EID: 70449572929     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH09-03-0169     Document Type: Article

References (31)

1. Abdollahi M, Cushman M, Rosendaal FR. Obesity: risk of venous thrombosis and the interaction with coagulation factor levels and oral contraceptive use. Thromb Haemost 2003; 89: 493-498. (Pubitemid 36329240)
2. Darvall KA, Sam RC, Silverman SH, et al. Obesity and thrombosis. Eur J Vasc Endovasc Surg 2007; 33: 223-233.
3. Oren E, Smith NL, Doggen CJ, et al. Body mass index and the risk of venous thrombosis among postmenopausal women. J Thromb Haemost 2006; 4: 2273-2275. (Pubitemid 44400310)
4. Pomp ER, le Cessie S, Rosendaal FR, et al.. Risk of venous thrombosis: obesity and its joint effect with oral contraceptive use and prothrombotic mutations. Br J Haematol 2007; 139: 289-296.
5. Rosendaal FR, Helmerhorst FM, Vandenbroucke JP. Female hormones and thrombosis. Arterioscler Thromb Vasc Biol 2002; 22: 201-210.
6. Stein PD, Beemath A, Olson RE. Obesity as a risk factor in venous thromboembolism. Am J Med 2005; 118: 978-980. (Pubitemid 41297761)
7. Canonico M, Oger E, Conard J, et al. Obesity and risk of venous thromboembolism among postmenopausal women: differential impact of hormone therapy by route of estrogen administration. The ESTHER Study. J Thromb Haemost 2006; 4: 1259-1265. (Pubitemid 43756703)
8. Canonico M, Oger E, Plu-Bureau, et al. Hormone therapy and venous thromboembolism among postmenopausal women: impact of the route of estrogen administration and progestogens: the ESTHER study. Circulation 2007; 115: 840-845. (Pubitemid 46294724)
9. Koh KK, Yoon BK. Controversies regarding hormone therapy: Insights from inflammation and hemostasis. Cardiovasc Res 2006; 70: 22-30.
10. Silvestri A, Gebara O, Vitale C, et al. Increased levels of C-reactive protein after oral hormone replacement therapy may not be related to an increased inflammatory response. Circulation 2003; 107: 3165-3169. (Pubitemid 36793086)
11. Vehkavaara S, Silveira A, Hakala-Ala-Pietila T, et al. Effects of oral and transdermal estrogen replacement therapy on markers of coagulation, fibrinolysis, inflammation and serum lipids and lipoproteins in postmenopausal women. Thromb Haemost 2001; 85: 619-625. (Pubitemid 32293696)
12. Zegura B, Guzic-Salobir B, Sebestjen M, et al.. The effect of various menopausal hormone therapies on markers of inflammation, coagulation, fibrinolysis, lipids, and lipoproteins in healthy postmenopausal women. Menopause 2006; 13: 643-650.
13. Bodary PF, Vargas FB, King SA, et al.. Pioglitazone protects against thrombosis in a mouse model of obesity and insulin resistance. J Thromb Haemost 2005; 3: 2149-2153. (Pubitemid 41727189)
14. Konstantinides S, Schafer K, Neels JG, et al.. Inhibition of endogenous leptin protects mice from arterial and venous thrombosis. Arterioscler Thromb Vasc Biol 2004; 24: 2196-2201.
15. Nagai N, Lijnen HR, Cleuren AC, et al. Factor V Leiden mutation is associated with enhanced arterial thrombotic tendency in lean but not in obese mice. Thromb Haemost 2007; 98: 858-863. (Pubitemid 47555080)
16. Nagai N, Hoylaerts MF, Cleuren AC, et al.. Obesity promotes injury induced femoral artery thrombosis in mice. Thromb Res 2008; 122: 549-555.
17. Tchaikovski SN, van Vlijmen BJ, Rosing J, et al.. Development of a calibrated automated thrombography based thrombin generation test in mouse plasma. J Thromb Haemost 2007; 5: 2079-2086. (Pubitemid 47450027)
18. Singh I, Smith A, Vanzieleghem B, et al. Antithrombotic effects of controlled inhibition of factor VIII with a partially inhibitory human monoclonal antibody in a murine vena cava thrombosis model. Blood 2002; 99: 3235-3240. (Pubitemid 34525303)
19. Day SM, Reeve JL, Myers DD, et al.. Murine thrombosis models. Thromb Haemost 2004; 92: 486-494.
20. Declerck PJ, Verstreken M, Collen D. Immunoassay of murine t-PA, u-PA and PAI-1 using monoclonal antibodies raised in gene-inactivated mice. Thromb Haemost 1995; 74: 1305-1309.
21. ter Horst SA, Fijlstra M, Sengupta S, et al.. Spatial and temporal expression of surfactant proteins in hyperoxia-induced neonatal rat lung injury. BMC Pulm Med 2006; 6: 8.
22. Moverare S, Skrtic S, Lindberg MK, et al.. Estrogen increases coagulation factor V mRNA levels via both estrogen receptor-alpha and -beta in murine bone marrow/bone. Eur J Endocrinol 2004; 151: 259-263. (Pubitemid 39213911)
23. Yamamoto Y, Moore R, Hess HA, et al. Estrogen receptor alpha mediates 17alpha-ethynylestradiol causing hepatotoxicity. J Biol Chem 2006; 281: 16625-16631. (Pubitemid 43909616)
24. Abu-Fanne R, Brzezinski A, Golomb M, et al. Effects of estradiol and raloxifene on arterial thrombosis in ovariectomized mice. Menopause 2008; 15: 98-104
25. Koh KK. Effects of estrogen on the vascular wall: vasomotor function and inflammation. Cardiovasc Res 2002; 55: 714-726.
26. Leng XH, Zhang W, Nieswandt B, et al.. Effects of estrogen replacement therapies on mouse platelet function and glycoprotein VI levels. Circ Res 2005; 97: 415-417.
27. Quehenberger P, Kapiotis S, Partan C, et al. Studies on oral contraceptive-induced changes in blood coagulation and fibrinolysis and the estrogen effect on endothelial cells. Ann Hematol 1993; 67: 33-36. (Pubitemid 23231383)
28. Simoncini T, Mannella P, Genazzani AR. Rapid estrogen actions in the cardiovascular system. Ann NY Acad Sci 2006; 1089: 424-430. (Pubitemid 47092056)
29. Fox SW, Chambers TJ. The effect of oestrogen on megakaryocyte differentiation and platelet counts in vivo. Int J Cardiol 2006; 109: 359-366.
30. Moro L, Reineri S, Piranda D, et al. Nongenomic effects of 17beta-estradiol in human platelets: potentiation of thrombin-induced aggregation through estrogen receptor beta and Src kinase. Blood 2005; 105: 115-121. (Pubitemid 40053072)
31. Moorthy K, Sharma D, Basir SF, et al.. Administration of estradiol and progesterone modulate the activities of antioxidant enzyme and aminotransferases in naturally menopausal rats. Exp Gerontol 2005; 40: 295-302.